BDX — Becton Dickinson and Company

Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on NYSE. It is led by Thomas E. Polen Jr., based in 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880, with about 70,000 employees. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 296.4% from 2025-06-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.

Use this BDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Becton Dickinson and Company even when a live quote feed is slow.